Targeted therapy in thyroid cancer

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 21, Issue 2, 2013, Pages 130-134

  Nixon, Iain J ^a   Shaha, Ashok R ^a   Tuttle, Michael R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

advanced thyroid cancer; anaplastic thyroid cancer; kinase inhibitors; medullary thyroid cancer; targeted therapy

Indexed keywords

B RAF KINASE; CABOZANTINIB; CISPLATIN; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PAZOPANIB; PLACEBO; SELUMETINIB; SORAFENIB; SUNITINIB; TIPIFARNIB; VANDETANIB;

ADVANCED CANCER; ALOPECIA; ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; BLEEDING; BRAIN METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG FATALITY; FOLLICULAR CARCINOMA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; INOPERABLE CANCER; LUNG METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 84875431892     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32835aa2c2     Document Type: Review

References (36)

1. Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery 2010; 148:1147-1152; discussion 1152-1143.
2. Olaleye O, Ekrikpo U, Moorthy R, et al. Increasing incidence of differentiated thyroid cancer in South East England: 1987-2006. Eur Arch Otorhinolaryngol 2011; 268:899-906.
3. Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011; 33:645-649.
4. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011; 21:231-236.
5. Morris LG, Myssiorek D. Improved detection does not fully explain the rising incidence of well differentiated thyroid cancer: a population-based analysis. Am J Surg 2010; 200:454-461.
6. Tsukahara K, Sugitani I, Kawabata K. Surgical management of tracheal shaving for papillary thyroid carcinoma with tracheal invasion. Acta Otolaryngol 2009; 129:1498-1502.
7. Nixon IJ, Whitcher M, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012; 22:884-889.
8. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987; 60:2372-2375.
9. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246:466-470; discussion 470-461.
10. Schilling T, Burck J, Sinn HP, et al. Prognostic value of codon 918 (ATG!ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001; 95:62-66.
11. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011; 165:315-322.
12. Hong DS, Cabanillas ME, Wheler J, et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 2011; 96:997-1005.
13. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95:2588-2595.
14. Shen Y, Ruan M, Luo QY, et al. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. Thyroid 2012.
15. Ciappuccini R, Trzepla G, Heutte N, et al. Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer. EJNMMI Res 2012; 2:18.
16. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011; 11:349.
17. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012; 18:2056-2065.
18. Brose MS. In search of a real "targeted" therapy for thyroid cancer. Clin Cancer Res 2012; 18:1827-1829.
19. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11:962-972.
20. Carr LL,Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDGPET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16:5260-5268.
21. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767-772.
22. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664-2671.
23. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134-141.
24. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration Drug Approval Summary. Clin Cancer Res 2012.
25. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28:2323-2330.
26. Frank-Raue K, Ganten M, Kreissl MC, Raue F. Rapid response to sorafenib in metastatic medullary thyroid carcinoma. Exp Clin Endocrinol Diabet 2011; 119:151-155.
27. Aller S, Popescu A, Rao S, et al. Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma. Pediatr Blood Cancer 2012; 58:98-100.
28. Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012; 19:209-216.
29. Ravaud A, de la Fouchardiere C, Asselineau J, et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010; 15:212-213; author reply 214.
30. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29:2660-2666.
31. Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Therapeut 2007; 6:1785-1792.
32. Gule MK, Chen Y, Sano D, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011; 17:2281-2291.
33. Antonelli A, Bocci G, La Motta C, et al. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2012; 97:E528-E536.
34. Perri F, Lorenzo GD, Scarpati GD, Buonerba C. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011; 2:150-157.
35. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012.
36. Chatal JF, Kraeber-Bodere F, Goldenberg DM, Barbet J. Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time. J Clin Oncol 2012; 30:2165.